Related Experiment Video

Updated: Oct 7, 2026

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
08:30

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice

Published on: April 19, 2011

[Anesthesia in coronary disease]

P Coriat1

  • 1Département d'anesthésie réanimation Groupe hospitalier La Pitié-La Salpêtrière 75013 Paris. pierre.coriat@psl.ap-hop-paris.fr

La Revue Du Praticien
|June 5, 2001
PubMed

Insights

Patients with coronary artery disease face high risk of myocardial infarct during non-cardiac surgery. Optimal management includes preoperatory revascularisation and prophylactic cardiovascular medications to reduce complications and improve survival.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Anesthesiology

Context:

  • Non-cardiac surgery poses significant risks for patients with coronary artery disease (CAD).
  • Myocardial infarct is a major postoperative complication in this high-risk group.
  • Current management relies on cardiac troponin I assessment.

Purpose:

  • To identify strategies for limiting postoperative cardiac complications in patients with CAD undergoing non-cardiac surgery.
  • To explore methods for improving the life expectancy of high-risk surgical patients.

Summary:

  • Patients with CAD undergoing non-cardiac surgery are at high risk for myocardial infarct.
  • Optimal postoperative management involves preoperatory myocardial revascularisation.
  • Prophylactic administration of cardiovascular medications (NSAIDs, beta-blockers, alpha 2 agonists) is recommended.

Impact:

  • Reduced incidence of postoperative coronary complications.
  • Improved survival rates for surgical patients with high cardiovascular risk.
  • Enhanced perioperative care protocols for CAD patients.

More Related Videos

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft05:25

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft

Published on: September 15, 2023

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
General Anesthesia: Overview01:24

General Anesthesia: Overview

Anesthesia is a medical procedure that uses drugs for CNS suppression to enable painless surgeries and procedures. The selection of anesthetics is influenced by their pharmacokinetic properties, side effects, and patient characteristics. Various types of anesthesia include general, local, regional, spinal, and inhalational.
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina I: Introduction01:30

Angina I: Introduction

Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...